The company's portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. Tonix has made significant strides with a $20 million registered direct offering and updates on its promising drug candidates, including TNX-4800 for Lyme disease prevention and TNX-4900 for chronic pain.
Cyborg Score Rationale
In 2024, TNXP's revenue was $10.09 million, an increase of 29.94% compared to the previous year. The company has achieved commercial milestone with Tonmya launch but faces substantial operating losses and a competitive biotech landscape requiring multiple clinical successes for long-term viability.
Top Insights
Tonmya is the first FDA-approved fibromyalgia treatment in over 15 years, representing a significant commercial opportunity in an underserved market.
TNX-4800, targeting seasonal Lyme disease prevention, plans an FDA meeting in 2026 to explore Phase 2/3 options with potential applicability to ~70 million people in U.S. Lyme-endemic areas.
Tonix licensed TNX-4900, a Sigma-1 receptor antagonist for chronic neuropathic pain, expanding its pain management portfolio.
The company is now in a commercial stage with its fibromyalgia treatment and appointed a new General Counsel to support growth.
Named Competitors
Fibromyalgia treatments — Established pain management franchise
Migraine therapeutics — Competing migraine prevention and acute treatments
CNS disorder therapies — Other CNS-focused biotech companies
Recent Developments
(February 2026) Scheduled to participate in two investor conferences in March
(January 2026) Presented Phase 3 RESILIENT data on TONMYA showing statistically significant pain reduction at Week 14
(December 2025) Completed $20 million registered direct offering and announced exclusive licensing of TNX-4900 for chronic neuropathic pain
Open the full interactive Tonix Pharmaceuticals Holding Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.